Harpoon Finds A Blood Cancer Partner In AbbVie
The immuno-oncology developer optioned its BCMA-targeting drug to AbbVie for $50m upfront, while it plans to retain a focus on solid-tumor candidates.
You may also be interested in...
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.